Home > Insider Trading > Filing (0001209191-21-012052)

Filing Details

Accession Number:: 0001209191-21-012052
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-18 18:12:26
Reporting Period:: 2021-02-16

Accepted Time:: 2021-02-18 18:12:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1666236	E. Steve Krognes	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	Cfo And Treasurer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-16	22,684	$64.27	927,316	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-02-16	10,199	$65.04	917,117	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-02-16	16,616	$66.20	900,501	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-02-16	501	$66.80	900,000	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	97,587	Direct

Footnotes

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.63 to $64.625 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.63 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.64 to $66.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.66 to $67.075 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 80,358 restricted stock units.